MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
Open Access
- 1 November 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 8 (11) , 1112-1119
Abstract
Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case–control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers. Cancer Prev Res; 8(11); 1112–9. ©2015 AACR.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Sporadic colon cancer murine models demonstrate the value of autoantibody detection for preclinical cancer diagnosisScientific Reports, 2013
- Genotype Directed Therapy in Murine Mismatch Repair Deficient TumorsPLOS ONE, 2013
- Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in WomenCancer Prevention Research, 2012
- Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor ModelsCancer Cell, 2011
- Use of a Single-Chain Antibody Library for Ovarian Cancer Biomarker DiscoveryMolecular & Cellular Proteomics, 2010
- Adenylate Kinase and AMP Signaling Networks: Metabolic Monitoring, Signal Communication and Body Energy SensingInternational Journal of Molecular Sciences, 2009
- Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screeningGut, 2009
- Use of high density antibody arrays to validate and discover cancer serum biomarkersMolecular Oncology, 2007
- Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical useEuropean Journal of Cancer, 2007
- A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)Nature Protocols, 2006